The bill, sponsored by two Democratic and one Republican lawmakers, comes following the deaths of two patients who developed tuberculosis linked to tainted bone grafts.
The bill would establish with the FDA that a test for TB in bone graft materials needs to be fast-tracked, according to the report.
Aziyo Biologics, which manufactured the material, voluntarily recalled its viable bone matrix products July 13. Infections stemmed from a single lot that initially tested negative for Mycobacterium tuberculosis before it was released.
At least 36 patients were treated with the products before the recall. Shipments from the contaminated lot were sent to 13 facilities in seven states — Michigan, California, Louisiana, New York, Oregon, Texas and Virginia — between Feb. 27 and June 20.
All of the unused units have since been pulled from hospitals and dental offices.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
